TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention.

Nicolas J, Baber U, Mehran R

Open source

DOI
10.15420/usc.2019.02
Published
2020
Container
US cardiology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.15420/usc.2019.02,
  title = {TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention.},
  author = {Nicolas J and Baber U and Mehran R},
  year = {2020},
  journal = {US cardiology},
  doi = {10.15420/usc.2019.02},
  url = {https://doi.org/10.15420/usc.2019.02}
}

RIS

TY  - JOUR
TI  - TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention.
AU  - Nicolas J
AU  - Baber U
AU  - Mehran R
PY  - 2020
JO  - US cardiology
DO  - 10.15420/usc.2019.02
UR  - https://doi.org/10.15420/usc.2019.02
ER  - 

APA

J, N., U, B., & R, M. (2020). TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention.. US cardiology. https://doi.org/10.15420/usc.2019.02

Source records